Organogenesis Holdings, Inc. is a pharmaceutical company based in the United States of America with a medium risk ESG score of 27.6. Specializing in regenerative medicine, the company focuses on developing, manufacturing, and commercializing product solutions for Advanced Wound Care, Surgical, and Sports Medicine markets. Its product categories include Advanced Wound Care and Surgical and Sports Medicine, all under the umbrella of regenerative medicine. Organogenesis Holdings, Inc. generates its highest revenue from Advanced Wound Care products such as PuraPly Antimicrobial, Affinity, NuShield, and more.